RETRACTED ARTICLE: LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration
Open Access
- 15 April 2020
- journal article
- retracted article
- Published by Springer Science and Business Media LLC in Journal of Ovarian Research
- Vol. 13 (1), 1-6
- https://doi.org/10.1186/s13048-020-00639-2
Abstract
Although lncRNA CTBP1-AS2 has been functionally analyzed only in cardiomyocyte hypertrophy and diabetes, analysis of TCGA dataset revealed its downregulation in endometrial carcinoma (EC), indicating its involvement in EC. In this study we found that CTBP1-AS2 was downregulated in EC and correlated with poor survival. MiR-216a might form base pairs with CTBP1-AS2 based on RNA-RNA interaction, which was confirmed by luciferase activity assay. Interestingly, upregulation of PTEN was observed after CTBP1-AS2 overexpression. Transwell assay showed that CTBP1-AS2 and PTEN overexpression led to decreased cancer cell invasion and migration and reduced enhancing effects of miR-216a on cell invasion and migration. It was known that miR-216a targeted PTEN. Therefore, CTBP1-AS2 may sponge miR-216a to upregulate PTEN, thereby suppressing endometrial cancer cell invasion and migration.Keywords
This publication has 16 references indexed in Scilit:
- Molecular Genetics of Endometrial CarcinomaAnnual review of pathology, 2019
- Uterine carcinosarcoma: A review of the literatureGynecologic Oncology, 2015
- Long non-coding RNAs: new players in cell differentiation and developmentNature Reviews Genetics, 2013
- Endometrial Cancer Risk Factors by 2 Main Histologic SubtypesAmerican Journal of Epidemiology, 2012
- Markers for individualised therapy in endometrial carcinomaThe Lancet Oncology, 2012
- Endometrial carcinoma: molecular alterations involved in tumor development and progressionOncogene, 2012
- Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)The Lancet Oncology, 2011
- Emerging therapeutic targets in endometrial cancerNature Reviews Clinical Oncology, 2011
- Molecular markers of endometrial carcinoma detected in uterine aspiratesInternational Journal of Cancer, 2011
- Risk factors in women 40 years of age and younger with endometrial carcinomaActa Obstetricia et Gynecologica Scandinavica, 2010